What’s Propelling Nabriva Therapeutics plc (NBRV) to Increase So Much?

April 17, 2018 - By Vivian Park

The stock of Nabriva Therapeutics plc (NASDAQ:NBRV) is a huge mover today! The stock increased 7.96% or $0.39 during the last trading session, reaching $5.29. About 671,453 shares traded or 154.75% up from the average. Nabriva Therapeutics plc (NASDAQ:NBRV) has declined 53.70% since April 17, 2017 and is downtrending. It has underperformed by 65.25% the S&P500.
The move comes after 6 months positive chart setup for the $194.23 million company. It was reported on Apr, 17 by Barchart.com. We have $5.66 PT which if reached, will make NASDAQ:NBRV worth $13.60M more.

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of novel antibiotics to treat serious bacterial infections with a focus on the pleuromutilin class of antibiotics. The company has market cap of $194.23 million. The Company’s lead product candidate is lefamulin, a novel semi-synthetic pleuromutilin antibiotic for systemic administration in humans. It currently has negative earnings. The companyÂ’s product, lefamulin is being studied in two registrational Phase 3 clinical trials in patients with moderate to severe community-acquired bacterial pneumonia.

Nabriva Therapeutics plc (NASDAQ:NBRV) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: